Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04138875
Other study ID # 2000029609
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date January 2022
Est. completion date December 2023

Study information

Verified date June 2022
Source Yale University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open label, risk-stratified, sequential treatment, phase 2 study of newly diagnosed post-transplant lymphoproliferative disorders with positive CD20 and CD30 expression. It includes an induction phase with rituximab and brentuximab vedotin (RBv), followed by a treatment phase with RBv or RBv in combination with bendamustine (RBvB) based on response to induction. The primary end point is treatment efficacy measured as the overall response rate (ORR) and progression free survival (PFS).


Description:

Post-Transplant Lymphoproliferative Disorders (PTLD) are defined by the revised 2017 edition of the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues as "lymphoid or plasmacytic proliferations that develop as a consequence of immunosuppression in a recipient of a solid organ, bone marrow or stem cell allograft". Within this definition 4 distinct categories exist, including: (1) Non-destructive PTLDs (plasmacytic hyperplasia, infectious mononucleosis, and florid follicular hyperplasia) (2) Polymorphic PTLD; (3) Monomorphic PTLD and (4) Classical Hodgkin Lymphoma type PTLD. The incidence of PTLD varies between different transplanted organs. Across all transplants monomorphic PTLD is the most common accounting for 75% of all cases. Lymphoma derived of B- cell origin account for the majority of cases (70%), while T-cell neoplasms represent a small minority (5%). Within monomorphic PTLD 50% of cases demonstrate association with the Epstein Barr Virus (EBV). Polymorphic PTLD accounts for 15-20% of all PTLD cases with the majority demonstrating EBV involvement. Early lesions account for 5% of PTLD and are all uniformly associated with EBV as are all the cases of Classic Hodgkin Lymphoma type PTLD. The current understanding of the pathogenesis of PTLD is incomplete. Despite concerted efforts, the investigators are unable to predict who will develop PTLD and do not understand why only 1 - 2% of all transplant recipients develop these disorders.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 2023
Est. primary completion date September 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Age = 18 and = 70 at the time of signing informed consent 2. Patient must have histologically confirmed newly diagnosed polymorphic or monomorphic PTLD defined according to the 2016 World Health Organization (WHO) classification criteria. 3. Diagnostic archival tissue available for review and correlative studies 4. Previous solid organ or allogeneic hematopoietic stem cell transplant 5. Measurable disease 6. Eastern Cooperative Oncology Group (ECOG) performance status = 2 7. Patients must have adequate organ and marrow function 8. Negative urine or serum pregnancy test for women of childbearing potential 9. Patients must be able to understand and to sign a written consent document. Exclusion Criteria: 1. Previous treatment for PTLD with the exception of immunosuppression reduction 2. Known involvement of the central nervous system by the PTLD 3. Known allergic reactions against foreign proteins 4. Uncontrolled inter-current illness including active infection, acute graft versus host disease and/or transplant organ rejection 5. Active concurrent malignancy with the exception of non-melanoma skin cancer, carcinoma in situ of the cervix or localized prostate cancer 6. Severe non-compensated diabetes mellitus 7. Pre-existing neuropathy grade 2 or greater 8. Pregnant or lactating 9. Psychiatric illness / social situations that would limit compliance with study requirements 10. Patients with previous hypersensitivity to Rituximab 11. Known HIV positive.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Rituximab
Rituximab is dosed at 375mg/m2 as an intravenous infusion. No adjustments are necessary for hepatic or renal impairment. Dosing will be done on baseline weight and height, however in patients who experience a >10% change in weight dosing will be readjusted.
Brentuximab Vedotin
Brentuximab vedotin is to be given as intravenous infusion at a dose of 1.2mg/kg during induction and 1.8mg/kg with each cycle. Dose reductions to 1.2mg/kg are allowed at investigator discretion.
Bendamustine
Bendamustine is to be given intravenously at a dose of 90mg/m2 on day 1 and day 2 of each high risk cycle. Dose reductions to 60mg/m2 are allowed at investigator discretion.

Locations

Country Name City State
United States Yale University New Haven Connecticut
United States Mayo Clinic Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Yale University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall response rate (ORR) (complete + partial response rate) Overall response rate (ORR) (complete + partial response rate) of the combination of rituximab, brentuximab vedotin +/-bendamustine in patients. Up to 84 days of treatment (4 cycles of treatment)
Primary Progression free survival (PFS) rate Progression free survival (PFS) of the combination of rituximab, brentuximab vedotin +/-bendamustine in patients. Up to 84 days of treatment (4 cycles of treatment)
Secondary ORR at the end of the induction phase ORR at the end of the induction phase with rituximab and brentuximab vedotin (RBv) in patients Up to 126 days of treatment (6 cycles of treatment)
Secondary Duration of response (DOR) duration of response (DOR) of the combination of rituximab, brentuximab vedotin +/-bendamustine in patients with newly diagnosed polymorphic and monomorphic CD20+ and CD 30+ PTLD. Up to 84 days of treatment (4 cycles of treatment)
Secondary Overall survival (OS) Overall survival (OS) of the combination of rituximab, brentuximab vedotin +/-bendamustine in patients with newly diagnosed polymorphic and monomorphic CD20+ and CD 30+ PTLD 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT02903810 - Combination Transfer of αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy Phase 1/Phase 2
Active, not recruiting NCT00710632 - Screening to Predict Weight Loss in Patients With Cancer N/A
Active, not recruiting NCT01056614 - Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies Phase 2
Terminated NCT00089089 - Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas Phase 1
Completed NCT03654404 - A Proof-of-Concept Trial of a Positive Psychology Intervention for Allogeneic Stem Cell Transplant Patients N/A
Completed NCT01212380 - Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL) Phase 1
Completed NCT00896792 - Nurse Practitioner Hospice Program for Patients With Terminal Metastatic Cancer and Their Families or Caregivers Early Phase 1
Recruiting NCT03110640 - Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma Phase 1
Completed NCT01982682 - Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor Phase 2
Completed NCT00833898 - Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT) Phase 3
Active, not recruiting NCT05147311 - Positive Psychology Intervention In HSCT N/A
Completed NCT04172818 - Feasibility Study of a Diary for Allogenic Hematopoietic Stem Cell Transplantation Patients and Families N/A
Completed NCT00670917 - Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy N/A
Withdrawn NCT00899808 - Molecular Markers and Genetic Markers in Patients Undergoing Radiation Therapy for Cancer N/A
Recruiting NCT02081937 - CART-19 Immunotherapy in Mantle Cell Lymphoma Phase 1/Phase 2
Completed NCT02194413 - Effects of Healing Touch on Patients Undergoing Hematopoietic Stem Cell Transplant N/A
Completed NCT01029366 - CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy Phase 1
Terminated NCT03121534 - Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation Phase 2
Withdrawn NCT01620229 - Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Phase 1/Phase 2
Completed NCT01866969 - Quality of Life in Caregivers of Hospitalized Older Patients With Cancer N/A